about
The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic targetInvasive growth: a MET-driven genetic programme for cancer and stem cellsInduction of epithelial tubules by growth factor HGF depends on the STAT pathwayInteractions between growth factor receptors and adhesion molecules: breaking the rulesPlasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth.Wild-type p53 controls cell motility and invasion by dual regulation of MET expressionA functional role for hemostasis in early cancer development.Cancer and blood coagulation.MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.Genetic link between cancer and thrombosis.Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor.Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1.Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.The MET oncogene is a functional marker of a glioblastoma stem cell subtype.The MET oncogene drives a genetic programme linking cancer to haemostasisHepatocyte Growth Factor: a marker and a player in disseminated intravascular coagulationActivation of the Met receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitroCancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report
P50
Q26852906-5EA6B4DA-DA76-4F1B-9FC3-94BE39095768Q28253680-1F3D28DC-B3DD-45BC-81F0-AB4CBEBAD035Q28259695-3D0822DB-2E62-42B3-88F2-452CC5AB9AEAQ28645747-8C3E66D7-1BA6-44BB-A138-2D82EAF085DFQ33783522-EFB1F37C-5CB1-4F6F-9FD3-D64963B1A1E3Q35180856-0DBD3D5C-DA6A-4EDD-9C79-D1389310A55DQ36276486-7615CCE2-F64E-4C52-96F3-7D4FBB44F402Q36448373-93C9A81F-1606-4B8E-9151-0A4B96A71FA8Q37458626-4F1EDCD5-92BB-40E3-8858-BB8E7BF8640FQ37593819-7DBD2B10-ED34-4BD6-94A0-A1F08C7EE054Q39564618-36FEF990-E625-4631-A5F2-F0B48B8DF8AAQ39692077-8533149A-F340-4527-972B-8771B1A371DDQ39893823-CBF3C940-D2D7-4E4D-A52F-1D01778DAFE2Q41954928-E1FECB62-EA79-46FE-A404-C2875AB83F93Q42505884-E6FAF349-F001-46D5-AE6E-BD23A1BF2F06Q42689844-58992DA7-9092-49E6-9C6A-D092DF68C74CQ42815104-2B545E2B-7442-441D-B365-FD1A01A7B8E4Q54357444-D34972B9-B67A-4B65-BAC1-CBB4DF312344Q55462084-2B2EA2A0-3A6A-4A33-8BE8-CEA210175587Q58165024-D1511000-6342-4BA8-AD5A-178974618CB8Q83820488-7D3B8F19-42AD-41C1-BA86-EE9EC6BC6F91Q90058426-6E2F333C-EC40-4223-81FD-A09062BD83BFQ96224808-8A957014-F85F-4509-8709-6C08E0533E25
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-2620-9083
@en
name
Carla Boccaccio
@ast
Carla Boccaccio
@en
Carla Boccaccio
@es
Carla Boccaccio
@nl
type
label
Carla Boccaccio
@ast
Carla Boccaccio
@en
Carla Boccaccio
@es
Carla Boccaccio
@nl
prefLabel
Carla Boccaccio
@ast
Carla Boccaccio
@en
Carla Boccaccio
@es
Carla Boccaccio
@nl
P106
P1153
7003360974
P21
P31
P496
0000-0003-2620-9083